The Latest Breaking News from Moderna

COVID-19 vaccines tweaked to better match today’s omicron threat are expected to roll out in a few weeks but how much will they help

Moderna stock inched higher late Tuesday just before announcing it asked the FDA to sign off on its updated Covid booster shot.

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

Roughly 29 million people are eligible for an autumn booster but there are just 13 million doses of the new bivalent Moderna jab available

The new jab is bivalent, meaning it protects against the original Covid strain as well as the Omicron variant

In the U.S., officials have asked vaccine makers to target BA.5, rather than the original omicron strain. That has delayed the boosters' development — but officials hope they will be more effective.

The Government has confirmed who will get another Covid injection and says new vaccine will be used

Moderna's bivalent vaccine is seen as the "next step" in COVID protection.

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…